Mettler Toledo International Inc Investor Event Transcript, Nov 11, 2026
Mettler Toledo International Inc (MTD)
Mettler Toledo reported 6% third-quarter growth and 13% EPS growth, with Asia Pacific and China each up 13%; it targets around 5% local currency revenue growth and low double-digit earnings growth in 2027, plus $950 million of repurchases. AI summary
Conference Transcript - MTD 2026-11-11
Doug Schenkel, Analyst — UBS
Good morning, everybody. I'm Doug Schenkel, and on behalf of UBS, it's my pleasure to welcome Sean Badala, Chief Financial Officer of Mettler Toledo. Thanks for being with us this morning.
Sean Badala, CFO
Hey, it's great to be here. Thanks for hosting me, Doug.
Doug Schenkel, Analyst — UBS
And so I think Mettler's well known to everybody here, everybody on the line, but it's evolved from its roots in precision weighting into a global leader across. Laboratory, process analysis, industrial and product inspection markets with what it believes are number one positions in most, if not all of those areas. The company did a really impressive investor day. Earlier this week, the company is now leveraging that leadership position in a long track record of strong, best-in-class execution to capture growth from automation, digitalization, and potential reshoring opportunities. So a lot of exciting things to talk about. That really probably sets the stage for what we're going to go through as a roadmap. I want to talk about the analyst day. Maybe, you know, we have a few questions there, and I want to talk about the messaging there. Kind of sort of related, maybe we could just start with, you know, a state of the union, state of the company, keeping in mind, you grew 6% or so organic in the third quarter at the analyst day. And on that call, you laid out an initial to 2027 outlook of around 5% local currency revenue growth, low double-digit earnings growth. What drove the strength in the quarter? And as you're thinking about 2027, what are you assuming in terms of the demand environment across your key end markets?
Sean Badala, CFO
Okay, great. Well, thanks, Doug. There's a lot to unpack there.
Doug Schenkel, Analyst — UBS
I look forward to the next half hour. Oh, yeah.
Sean Badala, CFO
You know, so I'll start with the third quarter. So very pleased with the third quarter, 6% growth, as you mentioned. What was nice to see is the breadth of the growth in our product portfolio. You know, if we, you know, on the industrial side, we were kind of comping, I think, a double digit growth on the core industrial side in the year before. So it was really nice to see growth on top of that. The trends that we continue to talk about with customer automation and digitalization really continue to kind of experience that. On the laboratory side, what was nice is that if you think about the beginning of the year, You know, the bioprocessing had really good trends. And then in the second quarter, we started to see, like, analytical instruments, laboratory balances like that, products that tend to sell to the QA, QC bench, you know, doing very well. And by Q3, we were starting to see stuff on the early research sides. For the first time in quite a while where we had, like, very good growth, like in liquid handling, you know, the pipettes and the pipette tips. So that was also really encouraging to see. Geographically, You know, Asia Pacific was clearly the highlight. You know, we were, Patrick and I were just there in September at the conclusion of our annual budget tour. High energy, as you can imagine. You know, each year when we go there, I feel like we're kind of, you know, kind of getting a pulse on the situation, and we walked away really encouraged. You know, we were, like, literally, you know, accelerating some additional investments into the region in terms of growth investments while we were there, just because, and not only China, but, like, the other parts of Asia Pacific. So, organically, Asia Pacific grew 13% in the quarter, but China also grew 13% in the quarter. And so that was great to see. We talked a little bit about that region and emerging markets more broadly in our second quarter call, and it was nice to see how that was playing out. And as we start talking LRPs and things like that, emerging markets in general, I think, is an area where we're really encouraged. And then, you know, you kind of take that and we were able to get 13% EPS growth, which we felt very good about. You know, that includes us continuing to invest in the business for the future, which we can talk a little bit more about with the LRP. And, you know, as we kind of like start to segue into, you know. 27 and stuff like that. We do feel like market conditions now are better than what we were seeing, and, you know, we're always a little bit cautious in how we, you know, how we look at things. You know, we're a little bit more cautious on Europe as an example. I think, you know, the European continent has experienced higher energy costs relative to the rest of the world. I think that's going to influence some of their decision making. And, you know, in some of our core segments, they're probably are investing more outside of Europe than they are in Europe at the moment. But, but still, you know, we feel like market conditions generally are a pretty good kind of going into next year. Now, maybe companies start a little cautious at the beginning of the year. But, but I think, you know, but generally, we have a probably more optimism, you know, at this point than we did a year ago.
Doug Schenkel, Analyst — UBS
Okay, that's great. And a couple follow ups. You mentioned Asia. You talked about China. China's about 16% of revenue. You had a really good third quarter. You're tracking to about 10% growth for the year. That's right. And you expect it to grow. I think you guys described that growing around the company average plus or minus over the long term with about 70% of sales to private companies. Based on the strength you're seeing, and then when you think about September's pharma plan, and then areas like batteries and new materials, areas where you play a pretty important role. Why couldn't it be better in China, and how do you think about investing more in China? Because it does seem like there's some pretty interesting growth opportunities for Mettler specifically there. Totally fair question.
Sean Badala, CFO
We're very optimistic on China. We're a little reserved with how we think about a longer-term guide. We just recognize that things can always change quickly in China. We've seen it go both ways many times over the years. But we're very favorable there, right? Like you said, we have a lot of competitive advantages in China. Like we've been there since the mid-'80s. We have a really great China-for-China footprint. Most of what we sell there, we make there. We are selling, as you say, directly. 70% of the time, we're selling, too. We have private companies, you know, and then we also have a multinational footprint. So like it's a very, I think, a more sustainable footprint in terms of like willingness to pay. The trends that we see in China. They're not unlike the rest of the world, but I do feel like there's a lot of speed in China, as there always is, you know, in terms of going after automation, going after digitalization, and those trends play very well to the strength of our portfolio, whether it be on the industrial side or whether it be in the laboratory side. And as you say, we're also very well aligned with the strategic priorities there. We've always had a very clear view of what the priorities are in the country in terms of pharmaceutical life sciences, but also clean energy. You mentioned battery as a subsegment there and some of these other hot segments. Our portfolio plays very well there. And what was nice to see is that with the reset in the market a few years ago, you know, we felt like it wasn't like there was being money throwing after the problem, right? You know, there was like a more organic recovery, you know, let's grow into the capacity. And then I think hopefully that's a little bit more sustainable going forward. But I think being aligned with those strategic categories is very important, like kind of going forward. And that definitely makes us feel positive going to the future. And, you know, like you said, there's certainly argumentation for an upside to that.
Doug Schenkel, Analyst — UBS
And as a follow-up, and you touched on part of what I'm about to ask, but one of the questions we get a lot is the localization you talked about. There's the COINS Act specific to biopharma, just as an example of why China for China is particularly important. Between your manufacturing footprint and all the supply chain changes that you made in the pandemic, coming out of the pandemic, it sounds like you feel really good about your ability to be nimble, regardless of what happens geopolitically within reason.
Sean Badala, CFO
Yeah, absolutely. I mean, especially today versus three years ago. Like, we kind of came out of COVID, like most companies, saying, like, how do we add more agility to our supply chain? And so we were already starting to think of, like, what are the appropriate more region-for-region strategies to invest in? And then with the onset of tariffs and trade disputes, a lot of companies accelerated those plans. But that didn't mean that we didn't do stuff in China for China. We did stuff in each region for its own region. And by doing those investments over the last four years, I feel like we're in a much stronger position, a more resilient position. But also, it's a better answer for our customers, right? Like, because you think about, like, delivery times and things like that. It's just a better answer. And so I do feel good about that. Now, like you said, there's limitations. There are topics in the world around, you know, electronics and other things that we, like all companies, we need to monitor closely. But I feel, you know, relatively like we're in a better position today, certainly, than we were in the past.
Doug Schenkel, Analyst — UBS
And this puts you in a position, again, correct me if I'm wrong, but I believe your 2027 view assumes tariffs return to earlier, higher rates. You're in a position to... Do you absorb the quote-unquote any of the changes like that, again, within reason, based on the footprint we just talked about, as well as Stern Drive, essentially all the initiatives you've taken more broadly to basically manage your way through it?
Sean Badala, CFO
Yeah, so just to even be more clear, we've assumed that the rates go back to the previous IEPA rates in our guidance. If they go... If we get back to the days of 145%, then that's another story. But within reason around IEPA, we should be good. That's how we thought about it.
Doug Schenkel, Analyst — UBS
Pricing. You expect price realization of around 2% over the longer term. I think if we heard that 10 years ago, we'd say that's pretty impressive in the current inflationary environment. How do we think about the ability to maybe get a little more price to basically manage things relative to cost?
Sean Badala, CFO
Fair question. That's kind of like our baseline view of the world, right? Like that's a normal inflationary environment. To the extent inflation is higher, I think you'll see us do better, just like you've seen us do better in the past. We didn't want to assume anything on that. We didn't want to assume that we're going to do incremental actions with a longer-term guide. But certainly, at elevated levels, we're monitoring that closely, and we'll continue to do appropriate measures as we see fit. But I think the bigger thing with pricing, too, is like you can do that if you have a strong value proposition, right? Like you just can't. It's not as simple as to saying like, hey, inflation is higher. We need more. Of course, maybe that's how some conversations go. But in the end, it really. Every time you have that kind of conversation, you're testing your value proposition, you know, and as a customer willing to pay and they're looking at their own budgets and they're looking at, you know, does this make sense? Now, our average price point is less than $10,000, so it helps, but we don't take that lightly. One of the things we talked about at the Investor Day is accelerating the pace of innovation. R&D spending is up 32% over the last five years. The stronger that value proposition, the more it supports that ability to have that pricing conversation.
Doug Schenkel, Analyst — UBS
Reshoring. You expect more than half of your manufacturing and QAQC exposure to benefit from U.S. onshoring. You've talked about greenfield sites taking three to five years to become fully operational. Yeah, some companies have thrown numbers out there, quantifying it. I think it's really hard to do this without introducing an element of false precision.
Sean Badala, CFO
Exactly.
Doug Schenkel, Analyst — UBS
That being said, can you help us?
Sean Badala, CFO
Exactly. Hey, we've obviously studied this very closely. There is a range here, and within that range, all joking aside, we didn't want to give this impression like, hey, here's the number. You know, like because it really can go in many directions. So when we reflected on it for this investor day, we said, hey, maybe what we'll do is we'll just kind of show everybody kind of like what we're seeing at a high level in terms of the activity, you know, back to like, is it real? And so you mentioned we have a big opportunity here. 50% of our sales are sold in production, 20% in QAQC. More than half of that we think would be what the product categories would be prime for this. We're a global company. We move well with these projects. A lot of these projects tend to be leaning into automation and digitalization. That fits us well also. So, but, but then. We have our Spinnaker program, right? And so we're not just waiting for the projects to come. We're monitoring things. And Spinnaker is, we've been doing it for a very long time. And, you know, within the program we call Top K within Spinnaker, we kind of monitor, like, different signals around the world, right? And so we have all these different external data signals. And we combine that with our knowledge inside the company. And I think it's that combination that takes a signal of, like, something you would see, like, hey, they announce it, they're going to invest, but then how do you turn that into actions, right? Like, that's what Top K is all about, is how do you take that and make it tangible right down to the salesperson? Who gets it? What's the contact information? And then what's all the information we know about that customer that creates a competitive advantage? And so when we just look at that beginning point of, like, the number of sites that are, you know, kind of in our database in terms of, like, new incremental investment sites, the number has significantly grown just in the last year or two, and we kind of, you know, provided some, like, year-to-date September numbers. So, like, to me, that's encouraging, but in terms of, like, The actual amount in the timeline, right? It's like both because, you know, a lot of these things are going to take three to five years to build. Most of our benefit will be on the back end as they build out these facilities. But what's nice is that previous to COVID, like. 80-90% of our business in the Western markets was just a replacement business. So, like, the fact that we're talking about greenfields, like, in, like, the U.S., and, you know, it's, like, very exciting, you know, and so it's, there's certainly incrementalism here. I know there's. We have discussions about, well, what does that mean for Europe? I think Europe might be a little softer in the mix of here, but still net-net, we feel like it's incremental. And it's going to be more redundancy maybe at customers, but that initial investment wave should help us.
Doug Schenkel, Analyst — UBS
And we didn't talk about this before, and it's a little bit hot off the presses given the election. It feels like the election was a while ago. It was last week. We had a policy discussion with the group last night. I think there's... There's more questions about the shape of reshoring, the shape of MFN coming out of the election. Clearly, this is a multi-year opportunity for you in its current form. If it changes shape, but we still keep in mind some of the underlying drivers for demand, does this, in a different form, do you think things drastically change from a long-term outlook standpoint if MFN were to change?
Sean Badala, CFO
I don't think so.
Doug Schenkel, Analyst — UBS
I mean, you don't have a lot in your model for 20.
Sean Badala, CFO
No, no, not. I mean, definitely not for 27. And, and like I said, the starting point for us, when we were looking at our own supply chain, it was like, we wanted to be more resilient anyhow, and we wanted to better serve customers. And I think, I think most industries are thinking very similarly. And it's just a question of how quickly do they move and over what period of time. But certainly when we're talking about longer term, you know, estimates, certainly I think those things are in motion, right? You can see initial activity in many regards.
Doug Schenkel, Analyst — UBS
We've touched on many of the highlights, and there's more from the Investor Day, and you guys always do a great job with those. What do you think is the biggest change? What's different this year from prior investor days as you're talking about Mettler? Essentially, what would you highlight as being the most incremental difference relative to what we've heard from you in the past?
Sean Badala, CFO
So maybe three things come to mind. One is we thought it was appropriate to reflect a little bit on the last few years and just also remind everyone how much we've been investing. I mentioned R&D already, but also in our own digitalization platforms. We have been investing in new growth programs as well, too, like service is a good example, and then this resilience topic. And so the beginning point is like we've been investing and we feel like we're well positioned for the future. Okay. The next thing is that, you know, while the LRP itself probably looks very similar to the last time we had one, right? But the number of drivers is way more than last time, way more. And that's exciting, right? And we already talked about some of them. And then the third thing is that, you know, we have this topic. So the concept of digitalization is not new for us, right? We've been doing Blue Ocean for, I don't know, almost 20 years and throughout that program. You know, we have a lot of advantages, you know, harmonized processes, but out of those processes, we have data, and then we can start to do all kinds of things. Now we apply the new technologies on top of it, and it's really neat to see. But we talked about, we spent a lot of time talking about, like, how, what digitalization means inside Mettler Toledo. So, like, there's three pillars there. One is, like, what are we doing to our own products to help our customers, whether AI wizards or imaging technologies. We gave a few examples. The second pillar is, what are we doing to engage with our customers? Which I think is super important as well, too, making their life a little bit easier, adding a little bit of value in terms of the experience. And then the third one is like a lot of companies, like, what are we doing inside? And we shared a lot of examples in terms of like the different use cases we have, you know, throughout the organization. I think we have like 5,000 agents. You know, deployed already inside the company. We have, you know, more than 100 different use cases for each of the different functional areas. R&D is a very rich opportunity for us that we've been doing things, but it's every functional area. And to me, that's... Like, that's very exciting. And it's not about just squeezing what you can squeeze out of this. It's more about, like, what does it mean in terms of being able to do more innovation? What does it mean to grow faster? And it's just like taking this whole resource reallocation topic and bringing it to the next level. And so to me, that was kind of neat. So we talked a lot about that, but then we talked about, and this was maybe a little similar to the past, but it has a new flavor to it because of AI, is like, what are we doing across the whole customer's value chain? In terms of our offering, and how do we, and we have such an advantage because we have all these, you know, leading instruments, as you mentioned, but those instruments are collecting information, and that the need for that information is more important than ever with all these AI programs, and now we provide a software layer above that, right? Like we have in the labs, we have LabX. Not only are we collecting it, we do it in a structured way, in a validated way, in a compliant way, and it just fits very nicely into all of our customers' digital and AI programs. And then on the back end of that, you know, hopefully there's some additional benefits with, you know, like in the pharmaceutical industry, you know, more drug candidates and ultimately more drug production. So those are the things that stood out to me that were a little bit more different than the past. But the baseline long-term strategies and what's prepared us for this moment, I mean, you don't get here in a year or a day, right? This has been many years in the making, and that's why it's so interesting.
Doug Schenkel, Analyst — UBS
Yeah, I mean, I don't remember you talking about hot segments. Yeah, yeah, yeah. I mean, what's that, $250 million in revenue today? Growing double digits. Yeah. And you feel pretty good about areas like semiconductors, data centers, batteries, new materials, all of those hot segments. You feel pretty good about those being positioned to not just grow 10% this year or next year. The durability is there.
Sean Badala, CFO
Yeah, I mean, if you just look at... Like, the fundamentals, right? Like, look at semiconductor, right? Like, and it's not a new topic. I mean, again, you know, coming out of like all the supply chain disruptions, post COVID, every, I think almost every country in the world, at least. That was my impression when I was on the annual budget tour. I'm like, oh my gosh, this is not just a two or three country topic. Everybody wants to have more autonomous control over their semiconductor supply chain. And so there's all kinds of different programs all around the world on this topic. Now, we see it in our own country. I see it in my backyard in Ohio, for sure. But that's the starting point. And then you layer on the electrification, global electrification trends, and then the needs of the future. And, you know, depending on your views of all that, I mean, it just feels like this is a, you know, we're going to see this for many, many years to come. And then when you think about... The time it takes to build a fab, it's not a short-term project, right? Like, this takes many years, and the biggest benefits will be towards the end when they're building out these plants. But that doesn't mean that it's not important for us to be talking to customers now to get spec'd in. So that's where Spinnaker is super critical.
Doug Schenkel, Analyst — UBS
A couple follow-ups. You service about a third of your serviceable install base today, which I think you've talked about being a $3 billion business. Each point, I just want to make sure I have this right, each point of added penetration contributes about 70 basis points to growth. To the total company growth. Do AI tools, such as the Technician Knowledge Hub, Change how quickly you can penetrate this opportunity.
Sean Badala, CFO
Yeah, I mean, I think, you know, something like that, first of all, it helps us with first-time fixed rates, right? So that's a great thing for our customers, and it gets them up and running, and it enhances our value proposition. The second thing is it gets our technicians up to speed much more quickly, right? So you hire a new technician. We've already started to see their onboarding time is shortened, so we're more productive. And the more productive we are, the more service we can do. And so, like, that's been... You know, we're seeing early innings opportunities here, but I think that's good. But then, you know, so that's a great example of how we leverage, like, large language models on top of our existing collaterals, right? And that's what's kind of cool about AI at Mettler is we have the Blue Ocean program with all this data, but we also have these corporate programs that we've been doing many years that have all this great information, right, all these materials, collaterals, and you put large language models on top of that. We have our own chat MT, probably like a lot of other companies, but then we can do things like this knowledge hub. And that's why I think when I talk about that third pillar of AI at Mettler, it's not just about the productivity. It's really about the insights that you're gaining and just the effectiveness that you are. But another example that we're doing here is, like, then using these technologies for scheduling, right? Like, so, and if we can just get one more visit scheduled a day, it's great. It's really great. It moves the needle. It moves the needle. And like you said, like, that's why we try to also frame, like, well, what does 1% mean? You know, like, and so it gives a little bit of a sense.
Doug Schenkel, Analyst — UBS
The LRP numbers, again, didn't look drastically different. The details you provided, as we just talked about, were. As I've walked around the last couple days here, a few folks have said to me, Mettler did a good job. It was interesting to hear them talk about a growth rate of X. If Mettler says X, they really mean Y, and they know they can get there. I'm not going to ask you what Y is, but guidance, philosophy, no change coming out of this analyst. I want to ask another AI question and maybe kind of tie AI and Autonomous Lab into the same thing. Mettler has an estimated, I think it's 40% of QA, QC, bench instruments, and LabX connectivity. Where does automation create incremental revenue opportunities? Because I think there's like a debate about in a world where there's more AI, there's more autonomous lab. Where do you win? And are there categories that maybe actually come under a little bit of pressure if momentum continues on this front?
Sean Badala, CFO
Yeah, so you mentioned, like you mentioned, in the QA, QC lab, up to 40% of the instruments, we have LabX, but we're also in the R&D labs, too, you know, and, you know, we, for those who were on site the other day, we showed an example in one of the workshops of what a typical autonomous lab could look like, you know, so we have our instruments, but then we also partner with external companies in terms of robotics, and what's interesting is that a customer can Um, usually by a wide range of instruments and then each day they can completely change what they want to do, you know, and, and then, you know, certain days it's going to be this combination of instruments and another day it's going to be other combinations. Now, fortunately for us, the laboratory balance is typically the most widely used instrument, you know, in a lab with sample preparation or whatever. Um, so that's a good one. And same with liquid handling, you know, like, you know, using individual pipettes as well too. So we're in a good spot there. Currently, You know, we're talking with, I think, about 120 autonomous labs around the world, and it's a global topic. You know, I mean, like we've talked about China as an example. You know, the Chinese move as fast as anybody on these types of topics.
Doug Schenkel, Analyst — UBS
A few companies have told me China is at another level when it comes to advancing autonomous labs.
Sean Badala, CFO
And, um, so, and, and I'd say so far we're, we've already, we're already in, we've already seen like a dozen of these labs already, you know, up and running.
Doug Schenkel, Analyst — UBS
Are you, is this showing up in your liquid handling business today?
Sean Badala, CFO
Um, yeah, yeah, but, but it's all, all of our businesses, all of our businesses. You know, just to temper expectations, this is super early innings, you know, a dozen labs is not, you know, with our price points, it's not a ton of dollars, but it's still like the trend itself is encouraging, you know, and the fact that we're well positioned for it is even more encouraging because, you know, it's hard to put dollars on these things. I've had a couple of questions recently on it. And of course, I ask our internal people the same question. And, you know, you always get the, it depends, right? It depends on what they want to do and the lab, blah, blah, blah. But in the end, you're going to have generally... More instruments, you know, so you can have all these different combinations. You're going to want to have, with us, with a common software layer like LabX, it helps to automate the workflows and communicate with the robots, but also collect all the data that it needs for its own, you know, AI purposes. And when you're doing all that, we're just really well positioned to sell presumably more instruments that are kind of like with this one software layer. And then if it's truly 24-7, there's going to be more use. Maybe what does that mean for future replacement, but what does that mean for future service? So there's a lot of questions that we still don't know. That's getting a little bit far out into the future, but there could be a lot of positives here, and hopefully our customers are also very successful with their programs, and we see ultimately more production coming out of these laps.
Doug Schenkel, Analyst — UBS
You did a nice job. We're covering where you play there from a QA, QC standpoint to where you play more upfront in terms of on the discovery side. One thing we've been thinking about is there's greater use of real-time analytics as bioprocessing titers increase, obviously. Any QAQC issues, they're really expensive. How are you positioned as AI plays a bigger role in, you know, basically trying to create better QAQC tools.
Sean Badala, CFO
In process analytics. Yeah, I mean, this is, I feel like a sweet spot for us, right? Like we're the first company to have an inline sensor and bioreactors that started off with pH. And then over the years, we've added a wide range of parameters. And so then that, like anything, right, if you're a company, you want to measure all the parameters, and it's nice to have one supplier and, frankly, one digital connection to one terminal to monitor and control all this stuff. And more recently... We just added glucose, you know, so like, you know, you want to monitor the living organisms, their oxygen, CO2, all this stuff, but then you also want to monitor how much you're feeding the organisms with, quote, sugar, you know, and so we can do that in an online basis, very new parameter for us, so something we're excited about, but we kind of look at this whole area as. There's increasing needs for higher quality sensors, more of them to make sure that they tightly control the batches because a bad batch is very expensive, but our sensors are also digital, you know, and so like that's a competitive advantage and some of them are smart, you know, where they collect all the information right in the sensor itself and they can tell you when it needs to be replaced as an example. So a lot of very cool things we're doing in this area, and I think by, once again, being a company that can broadly collect this information for our customers, they can then leverage that for their own. AI programs.
Doug Schenkel, Analyst — UBS
And I'm going to clumsily move over to industrial very quickly. Conceptually, it's some of the same principles that can drive better, even better positioning when it comes to areas like product and inspection.
Sean Badala, CFO
Yeah, so on the product inspection side, you know, Definitely, definitely similar. I mean, one of the things that's interesting there for us is just what we've done from an innovation perspective in terms of like, you know, coming out with some new products. We shared a few of those earlier this week. We've been kind of going after the mid-market opportunity as like a segment that was. We didn't focus on them a lot in the past. That's worked out very well. Now we've come out with, just very recently, new premium products as well, and that's being extremely well-received, too. So, like, that's fantastic. But then on the core industrial side, that even starts to sound more like the lab and process analytics side, where, like, that data integration, you know, like on the product inspection, we do. We have product software. We do that as well, too, and then you can kind of use that as a feedback loop to your customers in terms of, like, if you're seeing defects or contamination, but then. But then in core industrial, then that gets a little bit more into IoT topics and things like that. And we just literally came up with some new terminals. And that ability to integrate into our customers' systems is a huge advantage for us.
Doug Schenkel, Analyst — UBS
We're about out of time. I just want to make sure I get one last question in. So you talked about $950 million of repurchases for next year. You also on Monday pointed to life sciences, recurring revenue businesses such as software and service and distribution as key areas for potential bolt-ons. How actionable is the pipeline today?
Sean Badala, CFO
You know, we're always engaging in a pipeline. Just because we don't announce things doesn't mean we're not actively looking. We're just very disciplined, you know, when it comes to strategy and just making sure we have the right fit. But, you know, we have a good pipeline now, and we'll see how it turns out. But in the end, we feel very strongly about our organic story and, you know, a leader in very highly fragmented markets. We just need a little bit of market share, but we certainly like bolt-ons and, you know, it would be nice to see, you know, a couple additional ones in the future. But if it doesn't happen, we're still very – feel great about our organic story.
Doug Schenkel, Analyst — UBS
All right. That's fantastic, Sean. Let's leave it there. I really appreciate you being here.
Sean Badala, CFO
Yeah, thank you very much.